Table 2.
Baseline characteristics of patients in the prospective validation set
| Total (n = 317) | Severe (n = 5) | Non-severe (n = 312) | p value | |
|---|---|---|---|---|
| Age (years) | 30 (21–42) | 54 (39–66) | 30 (21–41) | 0.003 |
| Male, n (%) | 188 (59.3%) | 4 (80%) | 184 (59%) | 0.342 |
| Comorbidities, n (%) | 45 (14.2%) | 5 (100%) | 40 (12.8%) | < 0.001 |
| WBC (109/L) | 5.7 (4.5–6.8) | 4.7 (2.4–6.9) | 5.7 (4.5–6.8) | 0.343 |
| Lymphocyte (109/L) | 1.60 (1.22–2.02) | 1.01 (0.27–1.40) | 1.61 (1.22–2.02) | 0.008 |
| Platelet (109/L) | 227 (187–270) | 199 (154–243) | 228 (187–272) | 0.297 |
| CD3 (cell/μl) | 1170 (882–1529) | 611 (114–1038) | 1176 (893–1531) | 0.008 |
| CD8 (cell/μl) | 429 (301–585) | 151 (55–319) | 430 (303–588) | 0.002 |
| CD4 (cell/μl) | 621 (461–849) | 453 (54–630) | 622 (463–852) | 0.045 |
| CD45 (cell/μl) | 1630 (1234–2095) | 942 (261–1550) | 1634 (1240–2100) | 0.018 |
| CRP (mg/L) | 0.5 (0.5–1.12) | 13 (1–29) | 0.5 (0.5–1.11) | 0.025 |
| PCT (ng/mL) | 0.02 (0.02–0.03) | 0.02 (0.01–0.08) | 0.02 (0.02–0.03) | 0.299 |
| ALT (U/L) | 20 (13–31) | 26 (18–43) | 20 (12–31) | 0.281 |
| AST (U/L) | 19 (16–24) | 24 (19–49) | 19 (16–24) | 0.079 |
| LDH (U/L) | 193 (171–217) | 299 (197–385) | 193 (170–217) | 0.015 |
| TBIL (μmol/L) | 9.1 (7.2–12.3) | 15.5 (7.7–16.2) | 9.1 (7.2–12.3) | 0.241 |
| BUN (mmol/L) | 4.21 (3.57–5.03) | 5.81 (4.09–6.24) | 4.20 (3.56–5.01) | 0.072 |
| Creatinine (μmol/L) | 67 (56–76) | 74 (45–97) | 67 (56–75) | 0.720 |
| CK (U/L) | 77 (57–104) | 170 (109–209) | 76 (57–104) | 0.010 |
| D-dimer (ng/mL) | 0.28 (0.22–0.40) | 0.47 (0.31–1.64) | 0.28 (0.22–0.40) | 0.02 |
The p values indicate differences between severe and non-severe patients. p < 0.05 was considered statistically significant
WBC white blood count, CRP C-reactive protein, PCT procalcitonin, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT γ-glutamyl-transpeptidase, LDH lactate dehydrogenase, TBIL total bilirubin, BUN blood urea nitrogen, CK creatine kinase